Kinetics of neutralizing antibodies in patients naturally infected by H5N1 virus

BACKGROUND Little is known about the kinetics of anti-H5 neutralizing antibodies in naturally H5N1-infected patients with severe clinical illness or asymptomatic infection. METHODS Using H5N1 microneutralisation (MN) and H5-pseudotype particle-based microneutralisation assays (H5pp) we analyzed sera sequentially obtained from 11 severely ill patients diagnosed by RT-PCR (follow-up range 1-139 weeks of disease onset) and 31 asymptomatically infected individuals detected in a sero-epidemiological study after exposure to H5N1 virus (follow-up range: 1-2 month-11 months after exposure). RESULTS Of 44 sera from 11 patients with H5N1 disease, 70% tested positive by MN (antibody titre > or = 80) after 2 weeks and 100% were positive by 3 weeks after disease onset. The geometric mean MN titers in severely ill patients were 540 at 1-2 months and 173 at 10-12 months and thus were higher than the titers from asymptomatic individuals (149 at 1-2 months, 62.2 at 10-12 months). Fractional polynomial regression analysis demonstrated that in all severely ill patients, positive titers persisted beyond 2 years of disease onset, while 10 of 23 sera collected 10-11 months after exposure in asymptomatically infected individuals tested negative. CONCLUSIONS Our results indicate that people with asymptomatic H5N1 infection have lower H5N1 antibody titres compared to those with severe illness and that in many asymptomatically infected patients the antibody titer decreased to levels below the threshold of positivity within one year. These data are essential for the design and interpretation of sero-epidemiological studies.

[1]  J. Farrar,et al.  Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. , 2005, The New England journal of medicine.

[2]  D. Ha,et al.  Seroprevalence of anti-H5 antibody in rural Cambodia, 2007. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[3]  P. Sawanpanyalert,et al.  Kinetics and Longevity of Antibody Response to Influenza A H5N1 Virus Infection in Humans , 2009, Clinical and Vaccine Immunology.

[4]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[5]  Constance Schultsz,et al.  Avian influenza A (H5N1) in 10 patients in Vietnam. , 2004, The New England journal of medicine.

[6]  A. Vincent,et al.  Swine influenza viruses a North American perspective. , 2008, Advances in virus research.

[7]  Philippe Buchy,et al.  Low Frequency of Poultry-to-Human H5N1 Transmission, Southern Cambodia, 2005 , 2006, Emerging infectious diseases.

[8]  T. Uyeki,et al.  Low Frequency of Poultry-to-Human H 5 N 1 Virus Transmission , Southern Cambodia , 2005 , 2006 .

[9]  Ryo Takano,et al.  A comparison of the pathogenicity of avian and swine H5N1 influenza viruses in Indonesia , 2009, Archives of Virology.

[10]  J. Peiris,et al.  Optimization and evaluation of an influenza A (H5) pseudotyped lentiviral particle-based serological assay. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[11]  C. Bridges,et al.  Risk of influenza A (H5N1) infection among poultry workers, Hong Kong, 1997-1998. , 2002, The Journal of infectious diseases.

[12]  T. Uyeki,et al.  Lack of evidence of avian-to-human transmission of avian influenza A (H5N1) virus among poultry workers, Kano, Nigeria, 2006. , 2007, The Journal of infectious diseases.

[13]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .

[14]  A. Heath,et al.  Reproducibility of Serologic Assays for Influenza Virus A (H5N1) , 2009, Emerging infectious diseases.

[15]  J. Peiris,et al.  Molecular Epidemiology of Clade 1 Influenza A Viruses (H5N1), Southern Indochina Peninsula, 2004–2007 , 2009, Emerging infectious diseases.

[16]  J P Fox,et al.  Influenzavirus infections in Seattle families, 1975-1979. I. Study design, methods and the occurrence of infections by time and age. , 1982, American journal of epidemiology.

[17]  Yi Guan,et al.  Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia , 2006, Nature Medicine.

[18]  Keiji Fukuda,et al.  Evolution of H5N1 Avian Influenza Viruses in Asia , 2005, Emerging infectious diseases.

[19]  M. Peiris,et al.  Hemagglutinin pseudotyped lentiviral particles: characterization of a new method for avian H5N1 influenza sero-diagnosis. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[20]  Yi Guan,et al.  Oseltamivir resistance during treatment of influenza A (H5N1) infection. , 2005, The New England journal of medicine.

[21]  A. Hill,et al.  The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves , 1910 .

[22]  Philippe Buchy,et al.  Risk factors associated with subclinical human infection with avian influenza A (H5N1) virus--Cambodia, 2006. , 2009, The Journal of infectious diseases.

[23]  R. Gray,et al.  The role of male circumcision in the prevention of human papillomavirus and HIV infection. , 2009, The Journal of infectious diseases.

[24]  J. Peiris,et al.  Influenza A/H5N1 virus infection in humans in Cambodia. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[25]  Amy L. Vincent,et al.  Chapter 3 Swine Influenza Viruses , 2008 .

[26]  T. Uyeki,et al.  Seroprevalence of Antibodies to Avian Influenza Virus A (H5N1) among Residents of Villages with Human Cases, Thailand, 2005 , 2009, Emerging infectious diseases.

[27]  K. Ungchusak,et al.  Low Frequency of Infection with Avian Influenza Virus (H5N1) among Poultry Farmers, Thailand, 2004 , 2008, Emerging infectious diseases.